Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Ofstad · SciRah

Researcher profile · Semantic Scholar

A. Ofstad

Share profile

A. Ofstad — researcher profile on SciRah

h-index: 24
Works: 90
Citations: 2,679

Most-cited papers

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
F. Zannad, J. Ferreira, S. Pocock, S. Anker +7 more
2020The Lancet1,111 citations Open access
Semantic Scholar
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
S. Anker, J. Butler, G. Filippatos, M. Khan +16 more
2020Circulation265 citations Open access
Semantic Scholar
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial
M. Böhm, J. Slawik, M. Brueckmann, M. Mattheus +9 more
2019European Journal of Heart Failure98 citations Open access
Semantic Scholar
Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
G. Filippatos, J. Butler, D. Farmakis, F. Zannad +9 more
2022Circulation82 citations Open access
Semantic Scholar
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure.
M. Böhm, S. Anker, J. Butler, G. Filippatos +11 more
2021Journal of the American College of Cardiology68 citations Open access
Semantic Scholar
Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.
G. Savarese, N. Sattar, J. Januzzi, S. Verma +10 more
2019Circulation53 citations Open access
Semantic Scholar
The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions
A. Ofstad, D. Atar, L. Gullestad, G. Langslet +1 more
2018Heart Failure Reviews53 citations Open access
Semantic Scholar
Drink tests in functional dyspepsia: which drink is best?
I. Hjelland, A. Ofstad, J. Narvestad, A. Berstad +1 more
2004Scandinavian Journal of Gastroenterology50 citations
Semantic Scholar
Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
Priyadarshini Balasubramanian, C. Wanner, J. Ferreira, A. Ofstad +3 more
2022Journal of Clinical Endocrinology and Metabolism49 citations Open access
Semantic Scholar
Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced
S. Anker, M. S. Khan, J. Butler, A. Ofstad +10 more
2022European Journal of Heart Failure46 citations Open access
Semantic Scholar
Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation
G. Filippatos, D. Farmakis, J. Butler, F. Zannad +7 more
2023European Journal of Heart Failure43 citations Open access
Semantic Scholar
Association between uric acid levels and cardio‐renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA‐REG OUTCOME
S. Verma, Q. Ji, Deepak L. Bhatt, C. Mazer +8 more
2020Diabetes, obesity and metabolism43 citations Open access
Semantic Scholar
Empagli�ozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
A. Ceriello, A. Ofstad, I. Zwiener
202138 citations
Semantic Scholar
Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA‐REG OUTCOME trial
P. Pellicori, D. Fitchett, Mikhail N. Kosiborod, A. Ofstad +8 more
2021European Journal of Heart Failure38 citations Open access
Semantic Scholar
Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
J. Ferreira, D. Fitchett, A. Ofstad, B. Kraus +7 more
2020American Journal of Hypertension38 citations Open access
Semantic Scholar
Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
S. Inzucchi, K. Khunti, D. Fitchett, C. Wanner +4 more
2020Journal of Clinical Endocrinology and Metabolism38 citations Open access
Semantic Scholar
Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes.
S. Verma, C. Wanner, I. Zwiener, A. Ofstad +3 more
2019Journal of the American College of Cardiology37 citations Open access
Semantic Scholar
Body mass index and cardiorenal outcomes in the EMPEROR‐Preserved trial: Principal findings and meta‐analysis with the DELIVER trial
N. Sattar, J. Butler, Matthew M. Y. Lee, Josephine Harrington +12 more
2024European Journal of Heart Failure31 citations Open access
Semantic Scholar
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes
S. Kahl, A. Ofstad, B. Zinman, C. Wanner +4 more
2022Diabetes, obesity and metabolism31 citations Open access
Semantic Scholar
Identification of a definite diabetic cardiomyopathy in type 2 diabetes by comprehensive echocardiographic evaluation: A cross‐sectional comparison with non‐diabetic weight‐matched controls
A. Ofstad, S. Urheim, H. Dalen, E. Orvik +5 more
2015Journal of Diabetes31 citations Open access
Semantic Scholar
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA‐REG OUTCOME trial
S. Verma, Abhinav K. Sharma, B. Zinman, A. Ofstad +8 more
2020Diabetes, obesity and metabolism30 citations Open access
Semantic Scholar
Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial.
G. Savarese, A. Uijl, L. Lund, S. Anker +11 more
2021Journal of Cardiac Failure27 citations Open access
Semantic Scholar
Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR‐Preserved trial
M. Böhm, J. Butler, M. Krawczyk, F. Mahfoud +11 more
2023European Journal of Heart Failure26 citations Open access
Semantic Scholar
Comparison of the associations between non-traditional and traditional indices of adiposity and cardiovascular mortality: an observational study of one million person-years of follow-up
A. Ofstad, C. Sommer, K. Birkeland, M. Bjørgaas +3 more
2019International Journal of Obesity25 citations Open access
Semantic Scholar
Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
J. Ferreira, S. Verma, D. Fitchett, A. Ofstad +6 more
2020Cardiovascular Diabetology22 citations Open access
Semantic Scholar
Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline
J. Januzzi, J. Ferreira, M. Böhm, S. Kaul +8 more
2019European Journal of Heart Failure22 citations
Semantic Scholar
Myocardial dysfunction and cardiovascular disease in type 2 diabetes
A. Ofstad
2016Scandinavian Journal of Clinical and Laboratory Investigation22 citations
Semantic Scholar
Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME.
M. Böhm, D. Fitchett, A. Ofstad, M. Brueckmann +9 more
2020Journal of Hypertension20 citations
Semantic Scholar
Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
P. Pellicori, A. Ofstad, D. Fitchett, C. Zeller +5 more
2020ESC Heart Failure20 citations Open access
Semantic Scholar
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial
M. Vaduganathan, S. Inzucchi, N. Sattar, D. Fitchett +8 more
2021Diabetes, obesity and metabolism18 citations Open access
Semantic Scholar
Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial.
Abhinav K. Sharma, A. Ofstad, Tariq Ahmad, B. Zinman +7 more
2021JACC. Heart failure18 citations Open access
Semantic Scholar
Neutral impact on systolic and diastolic cardiac function of 2 years of intensified multi-intervention in type 2 diabetes: the randomized controlled Asker and Bærum Cardiovascular Diabetes (ABCD) study.
A. Ofstad, O. Johansen, L. Gullestad, K. Birkeland +4 more
2014American Heart Journal18 citations
Semantic Scholar
Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease
Abhinav Sharma, S. Inzucchi, J. Testani, A. Ofstad +6 more
2023ESC Heart Failure17 citations Open access
Semantic Scholar
Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
S. Verma, Lawrence A Leiter, B. Zinman, Abhinav K. Sharma +7 more
2021ESC Heart Failure17 citations Open access
Semantic Scholar
Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
J. Ferreira, B. Kraus, I. Zwiener, S. Lauer +7 more
2021Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease17 citations Open access
Semantic Scholar
Impact of polyvascular disease with and without co‐existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA‐REG OUTCOME
S. Verma, C. Mazer, S. Inzucchi, C. Wanner +6 more
2021Diabetes, obesity and metabolism13 citations Open access
Semantic Scholar
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
D. Vistisen, B. Carstensen, Patorno E. Elisabetta, S. Lanzinger +51 more
2023Cardiovascular Diabetology12 citations Open access
Semantic Scholar
Low-dose CT coronary angiography for assessment of coronary artery disease in patients with type 2 diabetes - A cross-sectional study
G. Ulimoen, A. Ofstad, K. Endresen, L. Gullestad +2 more
2015BMC Cardiovascular Disorders10 citations Open access
Semantic Scholar
Asymptomatic coronary artery disease in a Norwegian cohort with type 2 diabetes: a prospective angiographic study with intravascular ultrasound evaluation
S. Arora, A. Ofstad, G. Ulimoen, K. Birkeland +3 more
2019Cardiovascular Diabetology9 citations Open access
Semantic Scholar
Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials
Priyadarshini Balasubramanian, W. Kernan, K. Sheth, A. Ofstad +6 more
2023Stroke8 citations Open access
Semantic Scholar
High-density lipoprotein function is associated with atherosclerotic burden and cardiovascular outcomes in type 2 diabetes.
M. Heier, A. Ofstad, Mark S. Borja, C. Brunborg +5 more
2019Atherosclerosis7 citations Open access
Semantic Scholar
EMPAGLIFLOZIN IS ASSOCIATED WITH A LOWER RISK OF POST-ACUTE HEART FAILURE RE-HOSPITALIZATION AND MORTALITY: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL
J. Butler, G. Savarese, N. Sattar, J. Januzzi +10 more
2019Journal of the American College of Cardiology7 citations Open access
Semantic Scholar
Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome
Subodh Verma, Andrew Kosmopoulos, Deepak L. Bhatt, D. Fitchett +6 more
2023American Journal of Preventive Cardiology6 citations Open access
Semantic Scholar
Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR‐Pooled analysis
K. Talha, Jennifer B. Green, G. Filippatos, S. Pocock +9 more
2024Diabetes, obesity and metabolism5 citations Open access
Semantic Scholar
Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk.
Robert Weingold, B. Zinman, M. Mattheus, A. Ofstad +3 more
2023Journal of diabetes and its complications5 citations Open access
Semantic Scholar
Development of a tool to predict the risk of incident heart failure in a general population: the HUNT for HF risk score
A. Ofstad, C. Brunborg, O. Johansen, B. Mørkedal +4 more
2023ESC Heart Failure4 citations Open access
Semantic Scholar
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
D. Fitchett, S. Inzucchi, B. Zinman, C. Wanner +10 more
2021ESC Heart Failure4 citations Open access
Semantic Scholar
P2629Early benefits of empagliflozin in patients with type 2 diabetes with heart failure are not offset by increased adverse events: results from the EMPA-REG OUTCOME trial
P. Pellicori, A. Ofstad, D. Fitchett, C. Zeller +5 more
2019European Heart Journal4 citations
Semantic Scholar
Long-term follow-up of a hospital-based, multi-intervention programme in type 2 diabetes mellitus: impact on cardiovascular events and death
A. Ofstad, G. Ulimoen, E. Orvik, K. Birkeland +3 more
2017Journal of International Medical Research4 citations Open access
Semantic Scholar
The influence of diagnostic subgroups, patient- and hospital characteristics for the validity of cardiovascular diagnoses–Data from a Norwegian hospital trust
Cathrine Sæthern Rye, A. Ofstad, B. Åsvold, P. Romundstad +2 more
2024PLoS ONE3 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Wanner×25
Invite
C. Wanner — researcher profile on SciRah
B. Zinman×22
Invite
B. Zinman — researcher profile on SciRah
J. George×20
Invite
J. George — researcher profile on SciRah
D. Fitchett×20
Invite
D. Fitchett — researcher profile on SciRah

×14

Invite

M. Brueckmann — researcher profile on SciRah

S. Inzucchi×14

Invite

S. Inzucchi — researcher profile on SciRah

Invite

I. Zwiener — researcher profile on SciRah

Invite

F. Zannad — researcher profile on SciRah

Invite

J. Butler — researcher profile on SciRah

Invite

S. Verma — researcher profile on SciRah

J. Ferreira×10

Invite

J. Ferreira — researcher profile on SciRah

O. Johansen×10

Invite

O. Johansen — researcher profile on SciRah